Home Cell Therapy FDA Grants Breakthrough Therapy Designation to Novartis’s CAR-T Cell Therapy CTL019

FDA Grants Breakthrough Therapy Designation to Novartis’s CAR-T Cell Therapy CTL019

282
0
SHARE

The FDA granted a breakthrough therapy designation to Novartis’s CTL019, a chimeric antigen receptor T cell immunotherapy, or CAR-T, for the treatment of adult patients with relapsed and refractory diffuse large B-cell lymphoma that have failed two or more prior therapies.

During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the laboratory to create T cells that are genetically coded to hunt the patient’s cancer cells and other B-cells expressing a particular antigen.

The FDA accepted the company’s biologics license application filing and granted priority review for CTL019 in the treatment of pediatric and young adult patients with B-cell ALL. This is the second indication for which CTL019 has received this designation.

SHARE
Previous articleViaCyte to Present at Four Upcoming Healthcare Events
Next articleHealing wounds with cell therapy
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.

LEAVE A REPLY